Novartis Investigative Site

Kingsport, Tennessee 37660

0 studies enrolling now · 9 studies all time

What they study most

Age Related Macular Degeneration (AMD), Ankylosing Spondylitis, Choroidal Neovascularization, Chronic Plaque Psoriasis, Macular Degeneration, Moderate to Severe Allergic Asthma, Moderate to Severe Plaque-type Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Spondylitis, Ankylosing

Studies at this site

• Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis — Completed
• Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis — Completed
• Extension in AS: Sustainability of Benefits, Safety and Tolerability — Completed
• Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab — Completed
• A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD) — Completed
• 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis — Completed
• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1) — Completed
• Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma — Completed
• Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization — Completed